Have you already tested positive for Covid-19?
Do you have one of the Covid-19 related typical symptoms such as fever, cough or shortness of breath and are planning to get tested for Covid-19?
Are you older than 65 OR are you younger than 65, but with obesity or with risk factors such as diabetes, severe hypertension or cardiac disease?
If you already tested positive or will be tested positive for Covid-19, you may be eligible to participate in a study for a promising new medication to treat the disease.
The medication in the study can be taken orally once a day with no need for hospitalization during treatment.
For more information call the following number: 0800 454 54 54 (8am to 5pm).
The study miR-AGE is being conducted in high-risk Covid-19 participants. This includes individuals with pre-existing conditions which are at higher-risk to develop the severe form of Covid-19. These conditions are: obesity, diabetes, hypertension, cardiac disease and/or are age 65 and older.
The study medication, ABX464, has already been studied for other indications in hundreds of other participants and may prevent the participants in the Covid-19 study from developing the severe form of disease.
Participants enrolled in the study will beassisted by a responsible physician who will explain the details of the study, what they need to doand who will take care of them during the treatment.
If your test results are positive for Covid-19, you might be eligible participate in the study if you fall under one of the criteria below
(defined as BMI ≥ 30)
Recent history of uncontrolled High Blood Pressure (SBP > 150 mm Hg DBP >100 mm Hg)
.svg)
Treated diabetes (type I or II)
History of ischemic cardiovascular disease
Older than 65 years
.png)
Covid-19 is a respiratory illness that ranges from mild to severe symptoms. Usually, severe symptoms are more likely to be developed in patients who are part of the risk groups and currently there’s no coronavirus treatment available to avoid this escalation or treat those patients whose symptoms have already gone severe.
The medication is currently being studied for the treatment of chronic inflammatory diseases and has also been studied in participants with HIV. During these studies, the study medication showed three positive effects which are desirable to effectively treat participants with Covid-19 disease: Antiviral effect, Anti-inflammatory effect and Tissue repair effect.
Abivax is a biotechnology company based in France, founded in 2013 and listed on the Paris Stock Exchange since 2015. Abivax mobilizes the body’s natural immune system machinery to treat patients with inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (ABX464), COVID-19 (ABX464), HIV (ABX464), and liver cancer (ABX196). Abivax’s mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Dr. Jorge Kalil
Professor at FMUSP
miR-AGE Trial National Coordinator
CRM-SP 52834
.svg)
.svg)
